The Lancet Oncology (TLO)

Billions of dollars are currently being spent on the search for effective drugs that will stop disease before it happens. Advances in genetic testing are providing more opportunities to find out which diseases people are likely to be at risk of developing--but this knowledge has put huge pressure on the medical profession to come up with ways of avoiding disease altogether. This month's leading edge questions the ethical issues involved in chemoprevention and highlights the difficulties in obtaining reliable data from chemoprevention clinical trials. It concludes: "Genetic tests have created a demand for chemoprevention that is threatening to push medicine to its limits; health services could be stretched beyond capacity because they are treating healthy people as well as the sick. To stop this snowball effect it is essential that one simple idea is kept in mind: you can spend all the money in the world on preventive medicine, but when people won't even stop smoking, can it really work?"


Gastrointestinal stromal tumours (GISTs) are the most recent cancer type to be targeted by the most effective new drug of recent years--imatinib mesylate. Effective treatment of GISTs has been hindered in the past by their characteristic resistance to conventional chemotherapy and persistent misclassification of these tumours in clinical studies has made pre-2000 data difficult to interpret. However, it is now known that most GISTs contain a mutation in the KIT tyrosine kinase, which means they are an ideal target for imatinib. In their review, Heikki Joensuu and colleagues discuss the recent advances in understanding of these difficult-to-treat tumours and discusses the impact of imatinib on outcome for patients with GISTs. The authors conclude that imatinib "has provided physicians with a well-tolerated and highly effective therapeutic option for a disease for which no systemic therapy existed previously".

Contact: Richard Lane

Page: 1 2

Related medicine news :

1. The Lancet calls for the creation of a world institute for risk evaluation
2. The Lancet calls for creation of Intl Commission on Global Responses to Complex Emergencies
3. Majority of authors retract 1998 Lancet paper-Lancet editor points to implications
4. The Lancet Infectious Diseases (TLID)
5. The Lancet Neurology November press release
6. Lancet readers to join WHO election debate
7. The Lancet Oncology press release
8. The Lancet Neurology October press release
9. The Lancet neurology press release
10. The Lancet Neurology press release
11. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)

Post Your Comments:

(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... transport experience for the millions of people who require these medical transport services ... industry through the use of technology. Now, SmartEMS has put forth an industry-changing ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
Breaking Medicine Technology:
Cached News: